Fentanyl, the deadly synthetic opioid driving the nation’s high drug overdose rates, is also caught up in another increasingly serious problem: misinformation. False and misleading narratives on social media, in news reports, and even in popular television dramas suggesting people can overdose from touching fentanyl — rather than ingesting it — are now informing policy…
Aggressive deportation tactics have terrorized farmworkers at the center of the nation’s bird flu strategy, public health workers say. Dairy and poultry workers have accounted for most cases of the bird flu in the U.S. — and preventing and detecting cases among them is key to averting a pandemic. But public health specialists say they’re…
Because of past fraud by rogue brokers, some Affordable Care Act policyholders may get an unexpected tax bill this season. But that isn’t the only potential shock. Other changes coming soon — stemming from proposals by the administration of President Donald Trump — could affect their coverage and its cost. And sorting out related problems…
Matthew Thompson, M.D., of Telescope Health, explains his organization’s unique model
Through Teladoc’s new cardiometabolic health program, patients gain access to the BetterSleep app, a registered dietitian, health coaches, at-home testing and more. The post Teladoc Health Launches New Cardiometabolic Health Program appeared first on MedCity News.
Get notified about new policy research, polling, and news about the Medicaid financing debate and related issues.
OhioHealth is scaling an AI solution that it began piloting in 2022: Digital Diagnostics’ AI system that autonomously diagnoses diabetic retinopathy during primary care visits. The post How One Health System Is Embedding Diabetic Retinopathy Screening Into Primary Care appeared first on MedCity News.
“Taking away opportunities to get covered is not the way to eliminate fraud,” Young Invincibles’ director says
Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology. The post Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer appeared…
Report also calls on CMMI to narrow focus to conditions and procedures with significant cost variability, large patient volumes and clear opportunities to make improvements